drugset / Trial / NCT01375985

Safety Study of Single Administration Intravenous Treatment for Influenza

NCT01375985 ↗

Phase 1 Terminated 8 enrolled Sarepta Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-7100, a candidate treatment for influenza.

Timeline

Start
2011-06
Primary completion
2011-08
Completion
2011-11

Outcome

Outcome not reported

Stopped (Enrollment): “The study was halted after enrollment of the first cohort because of lack of funding”

Drugs

EvaluationDrugModalityDoseRoute
Subject RADAVIRSEN Antisense oligonucleotide — Intravenous

Indications